Kura Oncology and Xilio Therapeutics announced separate employment-inducement stock option grants effective October 1, 2026. Kura granted nonstatutory options covering 128,250 common shares to nine new employees, while Xilio granted non-qualified options covering 100,895 shares to two new employees and 105,000 shares to newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D. Kura’s options carry a $10.65 exercise price and Xilio’s carry an $8.91 exercise price, each matching the relevant company’s October 1 closing price. Both companies made the awards under Nasdaq Listing Rule 5635(c)(4), with options generally vesting 25% after one year and the remainder monthly over 36 months, subject to continued service. Kura develops precision cancer medicines, including FDA-approved KOMZIFTI® (ziftomenib), while clinical-stage Xilio develops masked immuno-oncology therapies designed to concentrate anti-tumor activity in the tumor microenvironment.